Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Benzinga01-04

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases. The analyst highlights that Denali is developing a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500033125?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-04 02:08","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2500033125","market":"us","top_or_hot":-1,"title":"Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic","media":"Benzinga","content":"<div>\n<p>William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases.\nThe analyst highlights that Denali is developing a ...</p>\n\n<a href=\"https://finance.yahoo.com/news/denali-therapeutics-neurodegenerative-disease-platform-180802032.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-04 02:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/denali-therapeutics-neurodegenerative-disease-platform-180802032.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases.\nThe analyst highlights that Denali is developing a ...</p>\n\n<a href=\"https://finance.yahoo.com/news/denali-therapeutics-neurodegenerative-disease-platform-180802032.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/denali-therapeutics-neurodegenerative-disease-platform-180802032.html","article_id":"2500033125","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500033125","pubTimestamp":1735927682,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"William Blair has initiated coverage on Denali Therapeutics Inc , a company focused on developing drugs for neurodegenerative diseases.The analyst highlights that Denali is developing a specialized transport vehicle  platform to enhance the delivery of treatments across the blood-brain barrier.It stands out from competitors with its promising potential for top-tier performance and scalability across different therapies and conditions.The company’s lead program Tividenofusp alfa, an enzyme-replacement therapy for Hunter syndrome, shows promise as a best-in-class treatment, the analyst highlights.The company has reached an agreement with the FDA on the requirements for accelerated approval and plans to submit a biologics license application in early 2025.Insights gained from tividenofusp alfa may also simplify the development and approval process for future treatments targeting other lysosomal storage diseases, such as DNL126 for Sanfilippo syndrome type A.Most recently, Denali Therapeut","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","QLD":"纳指两倍做多ETF","BK4581":"高盛持仓","LU0106831901.USD":"贝莱德世界金融基金A2","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK4504":"桥水持仓","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","BK4548":"巴美列捷福持仓","BK4127":"投资银行业与经纪业","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","USAW.SI":"AMZN 3xLongSG261006","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BIIB":"渤健公司","BK4516":"特朗普概念","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","TSYW.SI":"TESLA 3xLongSG261006","ALNY":"阿尔尼拉姆制药公司","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","IONS":"Ionis Pharmaceuticals, Inc","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LENZ":"Therapeutics","RARE":"Ultragenyx Pharmaceutical Inc","TV":"墨西哥电视",".IXIC":"NASDAQ Composite","BK4139":"生物科技","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","QID":"纳指两倍做空ETF","TQQQ":"纳指三倍做多ETF","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","NVIW.SI":"NVDA 3xLongSG261006","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","DNLI":"Denali Therapeutics Inc.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","RNA":"Avidity Biosciences, Inc.","PSQ":"纳指反向ETF","USJW.SI":"ALPHAB 3xLongSG261006","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SQQQ":"纳指三倍做空ETF","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1"},"translate_title":"Denali Therapeutics神经退行性疾病平台引发分析师乐观情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1,"LENZ":1,"IONS":1,"RARE":1,"RNA":1,"TV":1,"BIIB":1,"DNLI":0.9,".IXIC":0.9,"USJW.SI":0.6,"NVIW.SI":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases.\nThe analyst highlights that Denali is developing a specialized transport vehicle (TV) platform to enhance the delivery of treatments across the blood-brain barrier.\nIt stands out from competitors with its promising potential for top-tier performance and scalability across different therapies and conditions.\nThe company’s lead program Tividenofusp alfa, an enzyme-replacement therapy for Hunter syndrome, shows promise as a best-in-class treatment, the analyst highlights.\nWilliam Blair has initiated with an Outperform rating and a fair value of $35 per share.\nThe company has reached an agreement with the FDA on the requirements for accelerated approval and plans to submit a biologics license application in early 2025.\nInsights gained from tividenofusp alfa may also simplify the development and approval process for future treatments targeting other lysosomal storage diseases, such as DNL126 for Sanfilippo syndrome type A.\nMost recently, Denali Therapeutics initiated dosing in a global BEACON Phase 2a trial of BIIB122 (DNL151) for LRRK2-associated Parkinson’s disease.\nDenali’s market cap stands at $2.93 billion, with an enterprise value of $2.26 billion.\nCompared to its peers in neuroscience, rare diseases, and platform biotech, its valuation is lower than some but higher than others, reflecting the strength of its pipeline and technology.\nWilliam Blair notes the potential for significant growth as Denali advances its assets, including tividenofusp, which might receive accelerated approval and priority review by late 2025.\nIf additional clinical data reduces risks associated with its TV-enabled approach, Denali could achieve valuations similar to companies like Avidity Biosciences Inc. (NASDAQ:RNA), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Biogen Inc. (NASDAQ:BIIB), Alnylam Pharmaceuticals, Inc.(NASDAQ:ALNY), and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).\nPrice Action: DNLI stock is up 3.17% at $21.50 at the last check on Friday.\nRead Next:\n\nHedge Fund Giant Dan Loeb’s PG&E Bet Beats Market\n\nLatest Ratings for DNLI\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nJan 2022\nMorgan Stanley\nMaintains\n\nOverweight\n\n\nSep 2021\nOppenheimer\nInitiates Coverage On\n\nOutperform\n\n\nAug 2021\nMorgan Stanley\nMaintains\n\nOverweight\n\n\n\n View More Analyst Ratings for DNLI \n View the Latest Analyst Ratings \nUp Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.\nGet the latest stock analysis from Benzinga?\n\nThis article Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic originally appeared on Benzinga.com\n© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500033125"}